Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system

• Հիմնական հեղինակներ: Yifeng Bai (Հեղինակ), Xiaomei Wang (Հեղինակ), Xiaoqin Dai (Հեղինակ), Qinghua Ma (Հեղինակ), Honglin Hu (Հեղինակ)
• Ձևաչափ: Գիրք
• Հրապարակվել է: Frontiers Media S.A., 2024-10-01T00:00:00Z.
• Խորագրեր: article
• Առցանց հասանելիություն: Connect to this object online.

BackgroundThe discovery and development of immune checkpoint inhibitors (ICIs) have resulted in their application as a novel therapeutic strategy for patients with small-cell lung cancer (SCLC). However, a comprehensive analysis of the potential adverse effects of ICIs in patients with SCLC remains...